Altimmune, Inc. (NASDAQ:ALT) went up by 9.67% from its latest closing price when compared to the 1-year high value of $10.68 and move down -16.21%, while ALT stocks collected +25.89% of gains with the last five trading sessions. Press Release reported on 06/22/20 that Altimmune Announces IND Clearance for a Phase 2 Trial of HepTcell(TM) Immunotherapeutic for the Treatment of Chronic Hepatitis B
Altimmune, Inc. (NASDAQ:ALT) Worth an Investment?
Altimmune, Inc. (NASDAQ: ALT) The 36 Months beta value for ALT stocks is at 1.56, while of the analysts out of 0 who provided ratings for Altimmune, Inc. stocks as a “buy” while as overweight, rated it as hold and as sell. The average price we get from analysts is $13.00 which is -$9.19 below current price. ALT currently has a short float of 28.14% and public float of 10.43M with average trading volume of 2.67M shares.
ALT Market Performance
ALT stocks went up by 25.89% for the week, with the monthly jump of 13.60% and a quarterly performance of 182.77%, while its annual performance rate touched 312.11%. The simple moving average for the period of the last 20 days is 18.53% for ALT stocks with the simple moving average of 207.65% for the last 200 days.
Analysts’ Opinion on Altimmune, Inc. (NASDAQ:ALT)
Many brokerage firms have already submitted their reports for ALT stocks, with ROTH Capital repeating the rating for ALT shares by setting it to “Buy”. The predicted price for ALT socks in the upcoming period according to ROTH Capital is $13 based on the research report published on February 24, 2020.
ROTH Capital, on the other hand, stated in their research note that they expect to see ALT stock at the price of $8.30. The rating they have provided for ALT stocks is “Buy” according to the report published on July 19, 2019.
Piper Jaffray gave “Overweight” rating to ALT stocks, setting the target price at $6 in the report published on October 9, 2017.
ALT Stocks 65.96% Far from 50 Day Moving Average
After a stumble in the market that brought ALT to its low price for the period of the last 52 weeks, Altimmune, Inc. was unable to take a rebound, for now settling with -13.95% of loss for the given period.
The stock volatility was left at 12.21%, however, within the period of a single month, the volatility rate increased by 8.58%, while the shares surge at the distance of +12.35% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +169.50% upper at the present time.
In the course of the last 5 trading sessions, ALT went up by +25.89%, which changed the moving average for the period of 200 days to the total of +317.73% of gains for the stock in comparison to the 20-day moving average settled at $7.80. In addition, Altimmune, Inc. saw 386.24% in overturn over the period of a single year with a tendency to cut further gains.
ALT Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Altimmune, Inc. (ALT), starting from Venrock Healthcare Capital Par, who bought 1,500,000 shares at the price of $7.54 back on Jun 15. After this action, Rushing now owns 4,500,000 shares of Altimmune, Inc., valued at $11,310,000 with the latest closing price.
Venrock Healthcare Capital Par, the 10% Owner of Altimmune, Inc., bought 201,474 shares at the value of $8.72 during a trade that took place back on May 28, which means that Venrock Healthcare Capital Par is holding 3,000,000 shares at the value of $1,757,090 based on the most recent closing price.
ALT Stock Fundamentals
The current profitability levels are settled at -293.63 for the present operating margin. The net margin for Altimmune, Inc. stands at -353.71. Total capital return value is set at -35.43, while invested capital returns managed to touch -42.83. Equity return holds the value -46.20%, with -39.40% for asset returns.
Based on Altimmune, Inc. (ALT), the company’s capital structure generated 3.83 points for debt to equity in total, while total debt to capital is set at the value of 3.69. Total debt to assets is settled at the value of 3.23 with long-term debt to equity ratio rests at -7,591.28 and long-term debt to capital is 3.26.
The value for Enterprise to Sales is -1.85 with debt to enterprise value settled at -0.16. The receivables turnover for Altimmune, Inc. is 1.90 with the total asset turnover at the value of 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.04.